Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ-B3525 in Chinese patients with advanced cancers.

Zhi-Ming LiXiang LiSu LiRong TaoXin TianFan FengWenqi JiangHuaqing Wang

Published in: Cancer (2024)

TQ-B3525 exhibited rapid absorption and a nearly proportional increase in exposure. Acceptable safety and promising efficacy support further investigation of TQ-B3525 (20 mg once daily) for R/R lymphoma.

Keyphrases

diffuse large b cell lymphoma
open label
cell therapy
stem cells
loop mediated isothermal amplification
double blind